Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). (Q36400381)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). |
scientific article |
Statements
1 reference
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). (English)
1 reference
Scott Gettinger
1 reference
Pasi A Jänne
1 reference
Michel van den Heuvel
1 reference
Solange Peters
1 reference
Melissa L Johnson
1 reference
Marina C Garassino
1 reference
Daniel Christoph
1 reference
Chee Keong Toh
1 reference
Naiyer A Rizvi
1 reference
Jamie E Chaft
1 reference
Enric Carcereny Costa
1 reference
Jyoti D Patel
1 reference
Laura Q M Chow
1 reference
Marianna Koczywas
1 reference
Cheryl Ho
1 reference
Martin Früh
1 reference
Jeffrey Rothenstein
1 reference
Martin Reck
1 reference
Luis Paz-Ares
1 reference
Frances A Shepherd
1 reference
Takayasu Kurata
1 reference
Zhengrong Li
1 reference
Jiaheng Qiu
1 reference
Marcin Kowanetz
1 reference
Simonetta Mocci
1 reference
Geetha Shankar
1 reference
Alan Sandler
1 reference
13 June 2017
1 reference
1 reference
JCO2016719476
1 reference
1 reference
Identifiers
1 reference
1 reference